John Dorsey, MD
Hematology & Oncology · Greensboro, NCNPI 1396165585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,813 of the $24,783 with a category attached, or 79.9%. Pharmacosmos Therapeutics Inc. accounts for 90.6% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $8,768, more than ten times the $20 reported in 2020.
Across 58 payments — averaging $427.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$22K
- AstraZeneca$695
- E.r. Squibb & Sons, L.L.C.$575
- Bristol Myers Squibb$253
- Sobi, Inc$233
- EMD Serono, Inc.$120
- plus $464 from 11 others
What the payments were for
- Speaking & faculty fees$19,81380%
- Travel & lodging$1,5216%
- Food & beverage$3,42414%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 26 | $22,442 |
| AstraZeneca | 7 | $695 |
| E.r. Squibb & Sons, L.L.C. | 6 | $575 |
| Bristol Myers Squibb | 3 | $253 |
| Sobi, Inc | 2 | $233 |
| EMD Serono, Inc. | 1 | $120 |
| Johnson & Johnson | 2 | $113 |
| Karyopharm Therapeutics Inc. | 1 | $110 |
| Beigene USA, Inc. | 1 | $77 |
| Merck | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| Pfizer | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,783 in reported general payments places this provider in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 140 | $1,778,026 |
| RevlimidLenalidomide | 42 | $721,628 |
| ImbruvicaIbrutinib | 41 | $634,778 |
| CalquenceAcalabrutinib Maleate | 24 | $360,180 |
| PomalystPomalidomide | 16 | $349,298 |
| BrukinsaZanubrutinib | 17 | $241,843 |
| Abiraterone Acetate | 103 | $127,173 |
| EliquisApixaban | 110 | $97,780 |
| XareltoRivaroxaban | 44 | $48,278 |
| Xtampza ErOxycodone Myristate | 18 | $9,244 |
| Hydroxyurea | 56 | $2,320 |
| Dexamethasone | 68 | $1,077 |
| Potassium Chloride | 41 | $930 |
| Oxycodone Hcl | 52 | $822 |
| Acyclovir | 84 | $484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $253 | $721,62842 claims |
| AstraZenecaCalquence | $695 | $360,18024 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $575 | $349,29816 claims |
| Beigene USA, Inc.Brukinsa | $77 | $241,84317 claims |
| PfizerEliquis | $18 | $97,780110 claims |
| Johnson & JohnsonXarelto | $113 | $48,27844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Greensboro
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.